Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Insmed Inc (INSM)

Insmed Inc (INSM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 35,520,616
  • Shares Outstanding, K 213,273
  • Annual Sales, $ 363,710 K
  • Annual Income, $ -913,770 K
  • EBIT $ -1,152 M
  • EBITDA $ -1,132 M
  • 60-Month Beta 1.01
  • Price/Sales 116.37
  • Price/Cash Flow N/A
  • Price/Book 44.76

Options Overview Details

View History
  • Implied Volatility 49.93% (-5.71%)
  • Historical Volatility 60.25%
  • IV Percentile 50%
  • IV Rank 28.00%
  • IV High 92.41% on 04/10/25
  • IV Low 33.42% on 09/11/25
  • Expected Move (DTE 28) 17.26 (9.76%)
  • Put/Call Vol Ratio 0.67
  • Today's Volume 2,827
  • Volume Avg (30-Day) 3,521
  • Put/Call OI Ratio 1.13
  • Today's Open Interest 93,955
  • Open Int (30-Day) 86,991
  • Expected Range 159.47 to 193.98

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.39
  • Number of Estimates 8
  • High Estimate -1.08
  • Low Estimate -1.86
  • Prior Year -1.32
  • Growth Rate Est. (year over year) -5.30%

Price Performance

See More
Period Period Low Period High Performance
1-Month
161.02 +9.53%
on 12/18/25
212.75 -17.10%
on 12/02/25
-27.19 (-13.36%)
since 11/19/25
3-Month
134.01 +31.61%
on 09/26/25
212.75 -17.10%
on 12/02/25
+31.61 (+21.84%)
since 09/19/25
52-Week
60.40 +192.00%
on 04/09/25
212.75 -17.10%
on 12/02/25
+106.96 (+154.10%)
since 12/19/24

Most Recent Stories

More News
Stocks Settle Higher on Upbeat Tech Outlook and Cooling Inflation

The S&P 500 Index ($SPX ) (SPY ) on Thursday closed up by +0.79%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up by +0.14%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up by +1.51%. December...

AMAT : 256.41 (+1.15%)
GOOGL : 307.16 (+1.55%)
CNK : 22.27 (+1.55%)
AAPL : 273.67 (+0.54%)
SNDK : 237.61 (+8.27%)
MRK : 101.09 (+0.40%)
$IUXX : 25,346.18 (+1.31%)
ASML : 1,056.02 (+1.90%)
DJT : 16.09 (+8.28%)
ZNH26 : 112-160 (-0.22%)
MSFT : 485.92 (+0.40%)
TSLA : 481.20 (-0.45%)
Stocks Rally as Chip Makers Soar and US Price Pressures Ease

The S&P 500 Index ($SPX ) (SPY ) today is up by +1.28%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up by +0.82%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up by +1.91%. December E-mini S&P futures...

MSTR : 164.82 (+4.16%)
AMAT : 256.41 (+1.15%)
GOOGL : 307.16 (+1.55%)
CNK : 22.27 (+1.55%)
AAPL : 273.67 (+0.54%)
SNDK : 237.61 (+8.27%)
GLXY : 24.00 (+6.62%)
MRK : 101.09 (+0.40%)
$IUXX : 25,346.18 (+1.31%)
COIN : 245.12 (+2.47%)
ASML : 1,056.02 (+1.90%)
DJT : 16.09 (+8.28%)
Stocks Rebound on Strength in Chip Stocks and a Benign US CPI Report

The S&P 500 Index ($SPX ) (SPY ) today is up by +0.79%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up by +0.59%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up by +1.43%. December E-mini S&P futures...

MSTR : 164.82 (+4.16%)
AMAT : 256.41 (+1.15%)
CNK : 22.27 (+1.55%)
SNDK : 237.61 (+8.27%)
GLXY : 24.00 (+6.62%)
MRK : 101.09 (+0.40%)
$IUXX : 25,346.18 (+1.31%)
COIN : 245.12 (+2.47%)
ASML : 1,056.02 (+1.90%)
DJT : 16.09 (+8.28%)
ZNH26 : 112-160 (-0.22%)
ESH26 : 6,891.00 (+0.89%)
Insmed Provides Clinical and Business Update

—Phase 2b BiRCh Study of Brensocatib in CRSsNP Did Not Meet Primary or Secondary Efficacy Endpoints; Safety Consistent with Previous Studies; Insmed Discontinues CRSsNP Program—

INSM : 174.84 (+4.98%)
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BRIDGEWATER, N.J. , Dec. 4, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform...

INSM : 174.84 (+4.98%)
European Commission Approves BRINSUPRIâ„¢ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union

— Non-Cystic Fibrosis Bronchiectasis (NCFB) Is a Serious, Progressive Lung Disease That Can Lead to Permanent Lung Damage   —

INSM : 174.84 (+4.98%)
Insmed Strengthens Communities Worldwide During Fourth Annual Global Day of Good

More than 1,200 employees across the U.S., Europe, and Japan unite to support multiple organizations during annual company-wide day of service

INSM : 174.84 (+4.98%)
The Biotech Boom Gets a Trading Tool: How Direxion's Titans ETF Gives Access to the Sector's Top Performers

Amid the biotechnology sector's transformative era the Direxion Daily Biotech Top 5 Bull 2X ETF ($TBXU) offers traders a new, single-trade solution to gain 2X daily leveraged exposure to an e

ALNY : 400.23 (+1.06%)
EXEL : 44.30 (+4.06%)
GILD : 124.29 (+2.32%)
INSM : 174.84 (+4.98%)
UTHR : 517.13 (+2.00%)
Insmed To Present at November and December 2025 Investor Conferences

BRIDGEWATER, N.J. , Nov. 5, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform...

INSM : 174.84 (+4.98%)
Insmed: Q3 Earnings Snapshot

Insmed: Q3 Earnings Snapshot

INSM : 174.84 (+4.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 30%. The market has bounced from oversold territory. Beware of a potential mean reversion.

See More Share

Business Summary

Insmed is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas...

See More

Key Turning Points

3rd Resistance Point 183.51
2nd Resistance Point 177.91
1st Resistance Point 172.23
Last Price 174.84
1st Support Level 160.95
2nd Support Level 155.34
3rd Support Level 149.66

See More

52-Week High 212.75
Last Price 174.84
Fibonacci 61.8% 154.55
Fibonacci 50% 136.57
Fibonacci 38.2% 118.60
52-Week Low 60.40

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar